Novo Nordisk took equity in the buyer of the Parkinson's therapy it shelved
Cellular Intelligence has added Bob Langer and Yann LeCun to its scientific advisory board. The $62m to $70m it has raised now has to take STEM-PD, the cell therapy Novo Nordisk dropped, through Phase 2.
The Investor · Invest desk
What happened
- Cellular Intelligence said Monday that Bob Langer and Yann LeCun had joined its scientific advisory board, with Jens Nielsen of the BioInnovation Institute and Fabian Theis of Helmholtz Munich.
- The Boston company was known as Somite AI until January 2026, when it rebranded and published a white paper setting out what it calls cell fate engineering.
- Its largest round is a $47m Series A from May 2025 led by Khosla Ventures, with the Chan Zuckerberg Initiative and AMD Ventures among the participants.
Why it matters
- What it limits constraint Between $62m and $70m has to pay for the capsule data engine, the foundation model and a Phase 2 trial at the same time, so money spent generating more signal combinations is money not spent dosing patients.
- Who's exposed exposure Cellular Intelligence's shareholders now carry the cost of a Parkinson's trial that Novo Nordisk stopped funding, while Novo keeps a claim on the result through its equity stake.
- What it sets up precedent A large pharma company handing a discontinued cell therapy to a startup and taking equity back gives other shelved programs a route out that costs the seller little cash.
- What doesn't add up contradiction Fortune has LeCun leaving Meta last December to run AMI Labs; Crypto Briefing still calls him Meta's chief AI scientist. Which is current changes how much time a new adviser has to give.
Next story · Invest · yesterday
AstraZeneca's insitro deal puts 2.7% of its disclosed value up frontConfirmed4 publishers
Novo Nordisk did two things in the same May 2026 transaction. It gave up global rights to STEM-PD, an allogeneic Parkinson's cell therapy that it had shelved, and it took a strategic equity position in Cellular Intelligence, the company that picked the program up [5][6]. Cellular Intelligence now pays for the clinical work while Novo holds equity in the outcome. Neither Fortune nor Crypto Briefing reported the price of the asset or the size of the stake.
The balance sheet carrying that program is between $62m and $70m. The $47m Series A that Khosla Ventures led in May 2025, with the Chan Zuckerberg Initiative and AMD Ventures participating, is 67% to 76% of that [19][7][22]. That round closed 16 months before the board announcement [18]. The same money funds three things at once, which Langer described to Fortune as "a proprietary engine for generating biological data over time, an AI foundation model built to learn from that data, and an owned clinical program where it can test the practical value of its predictions" [11].
On the data side, Crypto Briefing reports the platform has gone from 27,000 experimental conditions to more than 1 million unique sequential signal combinations feeding transformer-style models, roughly a 37-fold increase. The capsule technology reportedly runs at more than 1,000 times the throughput of conventional methods [10][17][23]. The prediction results so far are internal. Langer told Fortune that early benchmarks beat existing models in both healthy development and cancer, "despite never training on a single cancer cell" [24].
Micha Breakstone, the chief executive, described the product to Fortune in world-model terms: "A world model learns how a system behaves and predicts what happens when you act on it" [8]. He added, "For us, the system is a living cell: the basic computational unit of life, receiving signals, processing information and changing its behavior in response" [9].
Reading four advisory seats as a capital signal needs care. Langer has co-founded roughly 40 companies and holds more than 1,500 issued and pending patents [12]. His name appearing on a cell-therapy startup is a frequent event; the observer seat on the board of directors is the less frequent part [4]. Breakstone also credited Fidji Simo, OpenAI's chief executive of applications, with shaping strategy as an advisor and consultant [16]. Langer told Fortune: "What matters to me is whether the science can lead to something that makes a difference for patients, and whether the people involved can carry it through" [13].
The announcements have come fast: renamed from Somite AI in January 2026, STEM-PD acquired in May, Arjun Raj named chief scientific officer in August, four advisers in September [2][5][14][1]. Crypto Briefing puts the company's focus on cell signaling dynamics, against Recursion Pharmaceuticals, Isomorphic Labs and Insilico Medicine working on molecular structure and drug-target interactions [15].
The two publishers do not agree on LeCun's employer. Fortune says he led Meta's Fundamental AI Research lab as chief AI scientist from 2013 to 2025 and left last December to launch AMI Labs, where he is executive chairman [20]. Crypto Briefing calls him Meta's chief AI scientist [21].
In my view the equity-for-asset structure tells you more than the four names do. Novo stopped paying for STEM-PD and kept a claim on it. That is a cheap option for the seller and a funded obligation for the buyer. If Novo's stake turns out to be large against the $62m to $70m raised, that read flips and the seller is co-funding the program it discontinued.
What to watch
- Whether Cellular Intelligence raises again before Phase 2 dosing begins, and at what valuation against the $47m Series A.
- Whether the prediction benchmarks Langer described turn up outside the company's own white paper and internal results.
- Whether Novo Nordisk discloses the size of its equity stake, or moves other discontinued programs on the same asset-for-equity terms.
Information, not investment advice. This story is general information about companies and markets, drawn from cited reporting. It is not a recommendation to buy, sell or hold any security; check the cited sources before acting.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence45
- Adoption15
- Hype gap+40
- Incentives65
- Confidence55
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Cellular Intelligence announced on Monday that Moderna co-founder Robert "Bob" Langer and Turing Award-winning AI researcher Yann LeCun joined its scientific advisory board, along with Jens Nielsen, chief executive of the Novo Nordisk Foundation's BioInnovation Institute, and Fabian Theis, who directs the Computational Health Center at Helmholtz Munich.
- [2]
The company, originally known as Somite AI, rebranded to Cellular Intelligence in January 2026 and released a white paper outlining its vision for "cell fate engineering".
- [3]
Boston-based Cellular Intelligence is trying to build an AI model that can predict and eventually control how living cells behave.
- [4]
Langer is also joining the company's board of directors as an observer.
- [5]
In May 2026 Cellular Intelligence acquired STEM-PD, an allogeneic cell therapy program for Parkinson's disease, from Novo Nordisk; the program holds FDA Fast Track designation and is ready for Phase 2 clinical trials, and Novo Nordisk simultaneously made a strategic equity investment as part of the deal.
- [6]
Fortune reports that the acquisition covered global rights to STEM-PD, an experimental Parkinson's disease cell therapy that Novo Nordisk shelved.
- [7]
The largest chunk of funding came from a $47 million Series A round in May 2025 led by Khosla Ventures, with the Chan Zuckerberg Initiative, AMD Ventures and other backers also participating.
- [8]
"A world model learns how a system behaves and predicts what happens when you act on it," Breakstone told Fortune.
- [9]
"For us, the system is a living cell: the basic computational unit of life, receiving signals, processing information and changing its behavior in response," Breakstone told Fortune.
- [10]
The company has scaled from an initial 27,000 experimental conditions to over 1 million unique sequential signal combinations, a dataset that feeds transformer-style AI models trained on dynamic cellular responses.
- [11]
Langer said the company is bringing "a proprietary engine for generating biological data over time, an AI foundation model built to learn from that data, and an owned clinical program where it can test the practical value of its predictions".
- [12]
Langer is an MIT Institute Professor, holds more than 1,500 issued and pending patents, has co-founded roughly 40 companies and received the National Medal of Science.
- [13]
"What matters to me is whether the science can lead to something that makes a difference for patients, and whether the people involved can carry it through," Langer told Fortune.
- [14]
The company appointed Arjun Raj as chief scientific officer in August 2026.
- [15]
Crypto Briefing says what distinguishes Cellular Intelligence from competitors Recursion Pharmaceuticals, Isomorphic Labs and Insilico Medicine is its focus on cell signaling dynamics rather than molecular structure or drug-target interactions.
- [16]
Breakstone credited OpenAI's chief executive of applications, Fidji Simo, with helping shape the company's direction while serving as a strategic advisor and consultant.
- [17]
The move from 27,000 experimental conditions to more than 1 million signal combinations is roughly a 37-fold increase.
- [18]
The May 2025 Series A closed 16 months before the September 2026 board announcement.
- [19]
Total funding for Cellular Intelligence sits between $62 million and $70 million.
- [20]
Fortune reports that LeCun won the 2018 ACM A.M. Turing Award, led Meta's Fundamental AI Research lab as chief AI scientist from 2013 to 2025, and left the company last December to launch AMI Labs, where he is executive chairman.
- [21]
Crypto Briefing describes LeCun as "Meta's chief AI scientist and a Turing Award winner".
- [22]
The $47m Series A is between 67% and 76% of total funding raised.
- [23]
The capsule technology reportedly offers more than 1,000x the throughput of conventional methods.
- [24]
Langer said early internal benchmarks show stronger prediction results than existing models in both healthy development and cancer, "despite never training on a single cancer cell".
Sources
2 independent publishers whose own reporting we read for this story.
- cryptobriefing.comModerna’s Bob Langer and Yann LeCun join Cellular Intelligence advisory board to advance AI in medicine
1 article · September 21, 2026
- fortune.comModerna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug
1 article · September 21, 2026
Topics and entities
Entities
- Micha Breakstone
- Yann LeCun
- AMI Labs
- Fidji Simo
- Novo Nordisk
- Khosla Ventures
- Cellular Intelligence